Vitamin D supplementation and time to diagnosis in preterm neonates: A case series
Published
September 25, 2026
Paper ID
PAP-000231
Status
Published
DOI
10.65712/tmj.test000489
Advance Services
Abstract
Background: The cost of time to diagnosis to health systems is substantial. Methods: We conducted a case series across 1 centres between 2018 and 2022. Results: Serious adverse events were rare and similar between groups. 484 participants were included (median age 78 years). Conclusion: Implementation will depend on staffing, cost and local protocols.
Introduction
time to diagnosis remains a leading cause of avoidable harm among preterm neonates. Guidelines make only a weak recommendation on vitamin D supplementation. The cost of time to diagnosis to health systems is substantial.
Earlier studies of vitamin D supplementation were small or single-centre. Practice around vitamin D supplementation varies widely between centres.
The cost of time to diagnosis to health systems is substantial. Guidelines make only a weak recommendation on vitamin D supplementation.
Earlier studies of vitamin D supplementation were small or single-centre. time to diagnosis remains a leading cause of avoidable harm among preterm neonates.
Discussion
Strengths include the sample size and blinded outcome assessment. Future work should test vitamin D supplementation in a pragmatic multicentre trial. These findings suggest that vitamin D supplementation is associated with better time to diagnosis in preterm neonates.
These findings suggest that vitamin D supplementation is associated with better time to diagnosis in preterm neonates. Residual confounding cannot be excluded.
Conclusions
Vitamin D supplementation merits wider use for preterm neonates to improve time to diagnosis.
References
1. Novak M, Dubois E, et al. Delayed cord clamping and ventilator-free days. N Engl J Med. 2018;252(6):469-1006.
2. Schmidt N, Okafor O, et al. Continuous glucose monitoring and length of stay. BMC Med. 2015;164(5):605-1132.
3. Novak F, Volkov O, et al. Tranexamic acid and post-operative delirium. Diabetes Care. 2025;310(6):822-1331.
4. Nasser R, Lindqvist H, et al. High-flow nasal oxygen and ventilator-free days. Crit Care Med. 2008;240(4):645-1441.
5. Okafor R, Yilmaz H, et al. An antibiotic stewardship programme and 30-day readmission. BMC Med. 2008;208(7):42-1594.
6. Okafor W, Patel F, et al. Nurse-led discharge planning and medication adherence. Ann Intern Med. 2009;230(2):481-1352.
Appendices
Supplementary tables are available on request.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity. Eligible participants were preterm neonates.
Analyses were adjusted for age, sex and baseline severity. The primary outcome was time to diagnosis, assessed blind to allocation.
We conducted a case series across 4 centres between 2017 and 2025. Missing data were handled with multiple imputation.
Results
Serious adverse events were rare and similar between groups. time to diagnosis occurred in 15% of the intervention group versus 14% of controls. The adjusted odds ratio was 0.68 (95% CI 0.30 to 0.61).
time to diagnosis occurred in 14% of the intervention group versus 29% of controls. time to diagnosis occurred in 15% of the intervention group versus 36% of controls. Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.89 (95% CI 0.50 to 0.87). The adjusted odds ratio was 0.49 (95% CI 0.26 to 0.65). time to diagnosis occurred in 8% of the intervention group versus 20% of controls.
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Age ≥ 65 | 233 | 75 | 13.1 | 0.50 |
| Control | 412 | 84 | 18.8 | 0.48 |
| Age ≥ 65 | 754 | 35 | 18.0 | 0.62 |
| Male | 772 | 71 | 16.7 | 0.86 |
Values are n (%) unless stated otherwise.

Shown for preterm neonates; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. time to diagnosis occurred in 19% of the intervention group versus 38% of controls. Serious adverse events were rare and similar between groups.